Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti‐PD ‐1 based immunotherapy in hepatocellular carcinoma

17 May 2022

Abstract excerpt

Hepatocellular carcinoma (HCC) is a severe disease with high mortality and global incidence. However, the interaction between the gut microbiome and combined immunotherapy for HCC is yet unclear. In this prospective clinical study, patients with unresectable HCC who had not received systemic treatment previously were recruited. Fecal and serum samples were collected at the baseline point and before each...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Gut microbiota and health
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35579980
DOI: 10.1002/ijc.34118

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti‐PD ‐1 based immunotherapy in hepatocellular carcinomaPMID 35579980Read ↗

Gut microbiota as a prognostic biomarker for unresectable hepatocellular carcinoma treated with anti-PD-1 therapySemantic proximity Read ↗

Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic targetSemantic proximity Read ↗

A Review of Gut Microbiota‐Derived Metabolites in Tumor Progression and Cancer TherapySemantic proximity Read ↗

Gut microbiome metabolites, molecular mimicry, and species-level variation drive long-term efficacy and adverse event outcomes in lung cancer survivorsSemantic proximity Read ↗

Integrated microbiome and metabolome analysis reveals the interaction between intestinal flora and serum metabolites as potential biomarkers in hepatocellular carcinoma patientsSemantic proximity Read ↗

The gut microbiota modulates responses to anti–PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumorsSemantic proximity Read ↗

Genomic Alterations and Microbiota Crosstalk in Hepatic Cancers: The Gut–Liver Axis in Tumorigenesis and TherapySemantic proximity Read ↗

Metagenomic and Metabolomic Correlates of Immunotherapy Response in Non-Small Cell Lung CancerSemantic proximity Read ↗

Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinomaSemantic proximity Read ↗

Exploring Hepatocellular Carcinoma Etiology through Multi-omics BioinformaticsSemantic proximity Read ↗

The Liver Microbiome Is Implicated in Cancer Prognosis and Modulated by Alcohol and Hepatitis BSemantic proximity Read ↗

Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.